Transcriptional Elongation Control of Hepatitis B Virus Covalently Closed Circular DNA Transcription by Super Elongation Complex and BRD4

Page view(s)
34
Checked on Feb 05, 2024
Transcriptional Elongation Control of Hepatitis B Virus Covalently Closed Circular DNA Transcription by Super Elongation Complex and BRD4
Title:
Transcriptional Elongation Control of Hepatitis B Virus Covalently Closed Circular DNA Transcription by Super Elongation Complex and BRD4
Journal Title:
Molecular and Cellular Biology
Keywords:
Publication Date:
12 September 2017
Citation:
Transcriptional Elongation Control of Hepatitis B Virus Covalently Closed Circular DNA Transcription by Super Elongation Complex and BRD4 Joel Celio Francisco, Qian Dai, Zhuojuan Luo, Yan Wang, Roxanne Hui-Heng Chong, Yee Joo Tan, Wei Xie, Guan-Huei Lee, Chengqi Lin Molecular and Cellular Biology Sep 2017, 37 (19) e00040-17; DOI: 10.1128/MCB.00040-17
Abstract:
Chronic hepatitis B virus (HBV) infection can lead to liver cirrhosis and hepatocellular carcinoma. HBV reactivation during or after chemotherapy is a potentially fatal complication for cancer patients with chronic HBV infection. Transcription of HBV is a critical intermediate step of the HBV life cycle. However, factors controlling HBV transcription remain largely unknown. Here, we found that different P-TEFb complexes are involved in the transcription of the HBV viral genome. Both BRD4 and the super elongation complex (SEC) bind to the HBV genome. The treatment of bromodomain inhibitor JQ1 stimulates HBV transcription and increases the occupancy of BRD4 on the HBV genome, suggesting the bromodomain-independent recruitment of BRD4 to the HBV genome. JQ1 also leads to the increased binding of SEC to the HBV genome, and SEC is required for JQ1-induced HBV transcription. These findings reveal a novel mechanism by which the HBV genome hijacks the host P-TEFb-containing complexes to promote its own transcription. Our findings also point out an important clinical implication, that is, the potential risk of HBV reactivation during therapy with a BRD4 inhibitor, such as JQ1 or its analogues, which are a potential treatment for acute myeloid leukemia.
License type:
Funding Info:
We thank Toby Wai Kiat Chin for generating BRD4 antibody. We are grateful to James E. Bradner for providing JQ1 for this study. This work was supported by funds provided by the Singapore A*STAR IMCB core fund (MR05010), the NMRC TCR flagship program (Eradication of HBV TCR Program, NMRC/TCR/014-NUHS/2015), and the BMRC YIG fund (BMRC024), as well as the Natural Science Foundation of Jiangsu Province of China (BK20160026), all to C.L.
Description:
ISSN:
0270-7306
1098-5549
Files uploaded:

File Size Format Action
57-143266-0-merged-1485224779.pdf 880.63 KB PDF Open